DSpace-CRIS

Now showing 1 - 3 of 3

Some of the metrics are blocked by your
consent settings
Comorbid Conditions in a Cohort of Inpatients with SARS-CoV-2 and their Association with In-Hospital Mortality During the Early Phases of the Pandemic
(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2023-12-01)
;
Cibrev, Dragan
;
;
Chamurovski, Nikola
;
Introduction: Studies determined that age and associated comorbidities are associated with worse outcomes for COVID-19 patients. The aim of the present study is to examine previous electronic health records of SARS-CoV-2 patients to identify which chronic conditions are associated with in-hospital mortality in a nationally representative sample. Materials and Methods: The actual study is a cross-sectional analysis of SARS-CoV-2 infected patients who were treated in repurposed hospitals. The study includes a cohort of patients treated from 06-11-2020 to 15-03-2021 for COVID-19 associated pneumonia. To examine the presence of comorbidities, electronic health records were examined and analyzed. Results: A total of 1486 in-patients were treated in the specified period, out of which 1237 met the criteria for case. The median age of the sample was 65 years. The overall in-hospital mortality in the sample was 25.5%, while the median length of stay was 11 days. From whole sample, 16.0% of the patients did not have established diagnoses in their electronic records, while the most prevalent coexisting condition was arterial hypertension (62.7%), followed by diabetes mellitus (27.3%). The factors of age, male gender, and the number of diagnoses showed a statistically significant increase in odds ratio (OR) for in-hospital mortality. The presence of chronic kidney injury was associated with the highest increase of OR (by 3.37) for in-hospital mortality in our sample. Conclusion: The study reaffirms the findings that age, male gender, and the presence of comorbidities are associated with in-hospital mortality in COVID-19 treated and unvaccinated patients. Our study suggests that chronic kidney injury showed strongest association with the outcome, when adjusted for age, gender, and coexisting comorbidities.
Some of the metrics are blocked by your
consent settings
Young people and COVID-19 in our country
(Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/ Sciendo, 2022)
;
Pop-Jordanova Nada
The current COVID-19 pandemic has raised significant mental health consequences across the world. Even though healthcare workers provide psychological services, the mental health of the overall population often is cause for concern. Psychosocial stressors of the population play a critical role in impacting both the spread of the disease and the occurrence of emotional distress and psychological disorder, during and after an infectious disease outbreak. The inability to plan, to anticipate future events, and to exert control, at least partially, over external variables inevitably generate stress and tension. Subsequently, this condition can generate more or less discomfort depending on the subjective evaluation of the individual, an evaluation which is influenced by the indi vidual’s stable personality traits. In fact, subjective experiences are never unique: stimuli endowed with the same stressful power do not necessarily cause these reactions in different individuals, while stressful conditions of varying degrees can induce the same response in different people. The aim of this research was to evaluate some aspects of mental health using answers related to this pan demic of a group young people, selected by chance. Results showed important changes in quality of life, insecurity, changes in mood and behaviour as well as not optimistic view for the future life. Discussion confirmed similar finding about young people opinions from other counties. Additionally, some mediating measures are proposed.
Some of the metrics are blocked by your
consent settings
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021)
(Macedonian Academy of Sciences and Arts/Sciendo, 2021-04-23)
;
Ridova Nevenka
;
Stojanoska, Tatjana
;
;
Abstract The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited.

Faculty of Medicine

Browse

Filters

Settings

Sort By

Results per page

Search Results